Evidence map›Paper›PMID 36678369›Full record

ReviewPathogens (Basel, Switzerland)2022

Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations.

Gabrielle Gimenes Lima, Amanda Izeli Portilho, Elizabeth De Gaspari

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Methods and Models for StudyingInternational journal of molecular sciences · 2024
    Review
  3. A novel approach to designing viral precision vaccines applied to SARS-CoV-2.Frontiers in cellular and infection microbiology · 2024
    Article
  4. Article
  5. Review
  6. Animal models for COVID-19 and tuberculosis.Frontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gabrielle Gimenes LimaImmunology Center, Adolfo Lutz Institute, São Paulo 01246-902, SP, Brazil.ORCID 0000-0001-6263-8462
Amanda Izeli PortilhoImmunology Center, Adolfo Lutz Institute, São Paulo 01246-902, SP, Brazil.ORCID 0000-0003-0875-5910
Elizabeth De GaspariImmunology Center, Adolfo Lutz Institute, São Paulo 01246-902, SP, Brazil.ORCID 0000-0001-8332-2248

Funding

National Council for Scientific and Technological Development 131308/2021-1National Council for Scientific and Technological Development 131412/2019-1São Paulo Research Foundation 18/04202-0
6 · The paper itself

Abstract

Since late 2019 and early 2020, with the emergence of the COVID-19 pandemic, scientists are rushing to develop treatment and prevention methods to combat SARS-CoV-2. Among these are vaccines. In view of this, the use of animals as experimental models, both to investigate the immunopathology of the disease and to evaluate the efficacy and safety of vaccines, is mandatory. This work aims to describe, through recent scientific articles found in reliable databases, the animal models used for the in vivo testing of COVID-19 vaccines, demonstrating some possibilities of more advantageous/gold-standard models for SARS-CoV-2 vaccines. The majority of the studies use rodents and primates. Meanwhile, the most adequate model to be used as the gold standard for in vivo tests of COVID-19 vaccines is not yet conclusive. Promising options are being discussed as new tests are being carried out and new SARS-CoV-2 variants are emerging.

Indexed as

animal modelcoronavirusgold standardnew variantsSARS-CoV-2vaccine

Identifiers

PMID36678369
PMCPMC9861368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.